Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | FPR1 | P21462 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27057694 | 1.00 | SLC6A2 (0.39) | SLC6A2FPR2FPR1PDE4BTRPV1 | |
| SCHEMBL25331737 | 0.87 | PDE4B (0.40) | SLC6A2FPR2FPR1PDE4BTRPV1 | |
| SCHEMBL27057711 | 0.85 | SCN9A (0.40) | SLC6A2FPR2FPR1PDE4BTRPV1 | |
| SCHEMBL25815779 | 0.84 | SLC6A2 (0.53) | SLC6A2SCN9A | |
| SCHEMBL27057831 | 0.84 | SLC6A2 (0.35) | SLC6A2FPR2FPR1SCN9AGPR119 | |
| SCHEMBL25815830 | 0.82 | SCN9A (0.40) | SLC6A2FPR2FPR1SCN9A | |
| SCHEMBL27057724 | 0.81 | SLC6A2 (0.39) | SLC6A2FPR2FPR1SCN9AGPR119 | |
| SCHEMBL25815814 | 0.81 | SLC6A2 (0.39) | SLC6A2FPR2FPR1BTKSCN9A | |
| SCHEMBL27057612 | 0.81 | SLC6A2 (0.39) | SLC6A2FPR2FPR1SCN9AGPR119 | |
| SCHEMBL8274756 | 0.80 | SCN9A (0.43) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | SLC6A2 4362/4885FPR2 2286/4885FPR1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.